##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 5 (2025)

Evolution of adult respiratory syncytial virus detection: impact of testing strategy changes and pandemic-related measures at a Swiss regional hospital, 2016–2023

Cite this as:
Swiss Med Wkly. 2025;155:4324
Published
20.05.2025

Summary

BACKGROUND AND AIMS: Respiratory syncytial virus (RSV) is increasingly recognised as an important cause of respiratory illness in adults. We aimed to analyse clinical and epidemiological characteristics of patients with a positive reverse transcription–polymerase chain reaction (RT-PCR) test in a Swiss regional hospital between 2016 and 2023, including predisposing factors, patient demographics, treatment approaches and clinical outcomes. We also examined temporal patterns of RSV detection during periods of changes in testing strategies and public health measures.

METHODS: In this retrospective cohort study at Spital Emmental, we analysed all consecutive in- and outpatients with respiratory symptoms who underwent nasopharyngeal RT-PCR testing following local syndrome-based testing protocols between December 2016 and February 2023. The testing methodology changed from trivalent (influenza A/B, RSV) to quadrivalent (SARS-CoV-2, influenza A/B, RSV) RT-PCR in March 2022, with simultaneous expansion of the testing criteria. Temporal patterns and incidence of positive RSV tests relating to periods of national COVID-19-related public health measures (13 March 2020 and 17 February 2022) were assessed.

RESULTS: Of 8135 RT-PCR tests performed, 231 (2.8%) were positive for RSV. The mean age was 69 years, with complete clinical data available for 194 patients. Of these, 157 (81%) required hospitalisation, of whom 19 (12%) were classified as nosocomial infections. Of the hospitalised patients, 14 (9%) required intensive care, with an in-hospital mortality rate of 6%. Major comorbidities in inpatients included cardiac disease (54%), pulmonary disease (49%) and anaemia (43%). Testing patterns showed marked temporal variation: 1766 tests (22%) were performed pre-pandemic, 125 (1%) during pandemic measures and 6244 (77%) after pandemic restrictions were lifted. The introduction of quadrivalent testing in March 2022 led to an increase in testing volume, but lower positivity rates (6% pre- vs 2% post-implementation).

CONCLUSIONS: Our results demonstrate RSV-associated resource use and mortality in adults. The temporal evolution of RSV detection in our cohort paralleled changes in testing practices, highlighting the complex interplay between diagnostic strategies and observed disease patterns in a regional hospital setting. Recently introduced preventive vaccination strategies may help to address the impact on patients and healthcare resource utilisation.

References

  1. Staadegaard L, Caini S, Wangchuk S, Thapa B, de Almeida WA, de Carvalho FC, et al. The Global Epidemiology of RSV in Community and Hospitalized Care: Findings From 15 Countries. Open Forum Infect Dis. 2021 Mar;8(7):ofab159. doi: https://doi.org/10.1093/ofid/ofab159
  2. Colosia A, Costello J, McQuarrie K, Kato K, Bertzos K. Systematic literature review of the signs and symptoms of respiratory syncytial virus. Influenza Other Respir Viruses. 2023 Feb;17(2):e13100. doi: https://doi.org/10.1111/irv.13100
  3. Woodruff RC, Melgar M, Pham H, Sperling LS, Loustalot F, Kirley PD, et al.; Respiratory Syncytial Virus Hospitalization Surveillance Network (RSV-NET). Acute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus Infection. JAMA Intern Med. 2024 Jun;184(6):602–11. doi: https://doi.org/10.1001/jamainternmed.2024.0212
  4. Simões EAF, DeVincenzo JP, Boeckh M, Bont L, Crowe JE, Griffiths P, et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis. 2015 Mar 15;211 Suppl 1(Suppl 1):S1–20.
  5. CDC. RSV Vaccine Guidance for Older Adults. Respiratory Syncytial Virus Infection (RSV). 2024. Available from: https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/older-adults.html
  6. Bundesamt für Gesundheit. Impfempfehlungen gegen Erkrankungen mit dem Respiratorischen Synzytial-Virus (RSV). Respiratorisches-Synzytial-Virus (RSV). BAG Bulletin 47. 2024. Available from: https://www.bag.admin.ch/bag/de/home/krankheiten/krankheiten-im-ueberblick/rsv.html
  7. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016 Sep;63(5):e61–111. doi: https://doi.org/10.1093/cid/ciw353
  8. Cepheid. Xpert Xpress CoV-2/Flu/RSV plus Package Insert. Available from: https://www.cepheid.com/en-CH/tests/respiratory/xpert-xpress-cov-2-flu-rsv-plus.html
  9. Chorazka M, Flury D, Herzog K, Albrich WC, Vuichard-Gysin D. Clinical outcomes of adults hospitalized for laboratory confirmed respiratory syncytial virus or influenza virus infection. PLoS One. 2021 Jul;16(7):e0253161. doi: https://doi.org/10.1371/journal.pone.0253161
  10. Schubert L, Steininger J, Lötsch F, Herdina AN, Redlberger-Fritz M, Tobudic S, et al. Surveillance of respiratory syncytial virus infections in adults, Austria, 2017 to 2019. Sci Rep. 2021 Apr;11(1):8939. doi: https://doi.org/10.1038/s41598-021-88537-5
  11. Markussen DL, Serigstad S, Ritz C, Knoop ST, Ebbesen MH, Faurholt-Jepsen D, et al. Diagnostic Stewardship in Community-Acquired Pneumonia With Syndromic Molecular Testing: A Randomized Clinical Trial. JAMA Netw Open. 2024 Mar;7(3):e240830. doi: https://doi.org/10.1001/jamanetworkopen.2024.0830
  12. Schober T, Wong K, DeLisle G, Caya C, Brendish NJ, Clark TW, et al. Clinical Outcomes of Rapid Respiratory Virus Testing in Emergency Departments: A Systematic Review and Meta-Analysis. JAMA Intern Med. 2024 May;184(5):528–36. doi: https://doi.org/10.1001/jamainternmed.2024.0037
  13. Chuang YC, Lin KP, Wang LA, Yeh TK, Liu PY. The Impact of the COVID-19 Pandemic on Respiratory Syncytial Virus Infection: A Narrative Review. Infect Drug Resist. 2023 Jan;16:661–75. doi: https://doi.org/10.2147/IDR.S396434
  14. Chow EJ, Uyeki TM, Chu HY. The effects of the COVID-19 pandemic on community respiratory virus activity. Nat Rev Microbiol. 2023 Mar;21(3):195–210.
  15. Hayes Vidal-Quadras C, Mrabet Deraoui I, Muehlethaler V. Impact of the COVID-19 pandemic on the epidemiology of bronchiolitis at Hôpital du Jura in Delémont, Switzerland: a retrospective observational study. Swiss Med Wkly. 2024 Jul;154(7):3768. doi: https://doi.org/10.57187/s.3768
  16. Haut ER, Pronovost PJ. Surveillance bias in outcomes reporting. JAMA. 2011 Jun;305(23):2462–3. doi: https://doi.org/10.1001/jama.2011.822
  17. Meyer Sauteur PM, Plebani M, Trück J, Wagner N, Agyeman PK, Meyer Sauteur PM, et al.; RSV EpiCH investigators. Ongoing disruption of RSV epidemiology in children in Switzerland. Lancet Reg Health Eur. 2024 Sep;45:101050. doi: https://doi.org/10.1016/j.lanepe.2024.101050
  18. Nygaard U, Hartling UB, Nielsen J, Vestergaard LS, Dungu KH, Nielsen JS, et al. Hospital admissions and need for mechanical ventilation in children with respiratory syncytial virus before and during the COVID-19 pandemic: a Danish nationwide cohort study. Lancet Child Adolesc Health. 2023 Mar;7(3):171–9. doi: https://doi.org/10.1016/S2352-4642(22)00371-6
  19. Munro AP, House T. Cycles of susceptibility: Immunity debt explains altered infectious disease dynamics post-pandemic. Clin Infect Dis. 2024; Available from: https://hal.science/hal-04731541